Table 1.
Baseline characteristics
| One or more comorbidities (n = 95) | No comorbidity (n = 315) | P‐value | |
|---|---|---|---|
| Treatment, N (%) | |||
| Vedolizumab | 49 (51.6) | 154 (48.9) | 0.646 |
| Ustekinumab | 46 (48.4) | 161 (51.1) | |
| Age (years), mean (SD) | 50.1 (16.1) | 39.4 (14.0) | <0.001 |
| Gender—female, N (%) | 57 (60.0) | 178 (56.5) | 0.546 |
| Body mass index, Mean (SD) | 25.2 (5.0) | 23.7 (4.5) | 0.029 |
| IBD type, N (%) | |||
| Crohn's disease | 71 (74.7) | 256 (81.3) | 0.375 |
| Ulcerative colitis | 23 (24.2) | 57 (18.1) | |
| IBD unclassified | 1 (1.1) | 2 (0.6) | |
| Disease duration (y), Median (IQR) | 12.4 (4.9‐19.9) | 11.0 (5.8‐18.8) | 0.697 |
| Treatment duration (wk), Median (IQR) | 51.9 (23.0‐101.4) | 48.9 (23.5‐94.3) | 0.501 |
| Follow‐up time (wk), Median (IQR) | 102.4 (52.0‐104.0) | 102.4 (52.0‐104.0) | 0.427 |
| Montreal classification | |||
| Age at diagnosis (y), N (%) | |||
| ≤16 | 7 (7.4) | 71 (22.5) | <0.001 |
| 17‐40 | 57 (60.0) | 204 (64.8) | |
| >40 | 31 (32.6) | 40 (12.7) | |
| Disease location (CD) a , N (%) | |||
| Ileum | 21 (29.6) | 80 (31.4) | 0.845 |
| Colon | 26 (36.6) | 84 (32.9) | |
| Ileocolonic | 24 (33.8) | 91 (35.7) | |
| Upper GI involvement (CD) a , N (%) | 5 (7.0) | 18 (7.1) | 0.996 |
| Disease behaviour (CD) a , N (%) | |||
| Inflammatory | 37 (52.1) | 135 (52.9) | 0.348 |
| Stricturing | 22 (31.0) | 65 (25.5) | |
| Penetrating | 9 (12.7) | 50 (19.6) | |
| Unknown | 3 (4.2) | 5 (2.0) | |
| Peri‐anal disease (CD) a , N (%) | 8 (11.3) | 49 (19.4) | 0.117 |
| Disease location (UC/IBD‐U) a , N (%) | |||
| Proctitis | 2 (8.3) | 4 (6.8) | 0.892 |
| Left‐sided colitis | 11 (45.8) | 25 (42.4) | |
| Pancolitis | 10 (41.7) | 28 (47.5) | |
| Unknown | 1 (4.2) | 2 (3.4) | |
| Prior intestinal resections, N (%) | 43 (45.3) | 148 (47.0) | 0.768 |
| Prior anti‐TNF therapy (ever use anti‐TNF), N (%) | 85 (89.5) | 311 (98.7) | <0.001 |
| Prior VEDO therapy, N (%) | 10 (21.7) | 72 (44.7) | 0.005 |
| Prior USTE therapy, N (%) | 1 (2.0) | 6 (3.9) | 0.535 |
| Clinical disease activity, median (IQR) | |||
| HBI | 8.0 (5.0‐10.0) | 7.0 (5.0‐10.0) | 0.079 |
| SCCAI | 5.0 (3.0‐7.0) | 6.0 (3.5‐9.0) | 0.519 |
| Biochemical disease activity, median (IQR) | |||
| CRP (mg/L) | 6.0 (3.0‐16.0) | 8.0 (2.0‐21.0) | 0.319 |
| FCP (μg/g) | 552.0 (197.5‐1223.8) | 932.5 (296.8‐1999.5) | 0.044 |
| Concomitant medication, N (%) | |||
| No immunosuppressants | 44 (46.3) | 142 (45.2) | 0.953 |
| Corticosteroid or immunomodulator | 42 (44.2) | 139 (44.3) | |
| Both corticosteroid and immunomodulator | 9 (9.5) | 33 (10.5) | |
Missing data: age 1 missing; BMI 134 missing; disease duration 1 missing; treatment duration 1 missing; follow‐up time 1 missing; disease location (CD) 1 missing; upper GI involvement 1 missing; perianal disease 3 missing; HBI 10 missing; SCCAI 2 missing; CRP 87 missing; FCP 180 missing; concomitant medication 1 missing.
Abbreviations: anti‐TNF, anti‐tumor necrosis factor; CD, Crohn's disease; CRP, C‐reactive protein; FCP, fecal calprotectin. ; GI, gastrointestinal; HBI, Harvey Bradshaw Index; IBD, inflammatory bowel disease; IBD‐U, IBD‐Unclassified; IQR, interquartile range; N, number; SCCAI, simple clinical colitis activity index; SD, standard deviation; UC, ulcerative colitis.
a
Maximum extent until exclusion.